Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on TVTX.

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Good morning, and welcome to Travere Therapeutics Business Update Call. Today's call is being recorded. At this time, I would like to turn the conference over to Nivi Nehra, Vice President of ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization ...

SAN DIEGO, June 11, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement ...